Neurological Biomarkers Market - Global Industry Analysis

Neurological Biomarkers Market - By Application (Alzheimer’s Disease, Parkinson’s Disease, Autism Spectrum Disorders, Multiple Sclerosis, and Others), By Type (Proteomic, Genomic, Imaging, Metabolomic, and Others), By End-User (Independent Clinical Diagnostic Centers, Hospital Laboratories, Research Organizations, and Others), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

Published Date: 24-Aug-2020 Category: Medical Device Report Format : PDF Pages: 110 Report Code: ZMR-3403 Status : Published

Global Neurological Biomarkers market, which accrued nearly 6,371.69 (USD Million) in 2019, is set to record the CAGR of 14.5% over the period from 2020 to 2026.

Description

The global Neurological Biomarkers market, which accrued nearly 6,371.69 (USD Million) in 2019, is set to record the CAGR of 14.5% over the period from 2020 to 2026. The report offers assessment and analysis of the Neurological Biomarkers market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, sales estimates, opportunities, evolving trends, and industry-validated data. The report offers historical data from 2017 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million).

Introduction

Neurological biomarkers are utilized for detecting the persons at the risk of having neurological ailments and some of these biomarkers are used for diagnosing the disorder, determine its progress, and estimate the disease result. In therapeutic surroundings, these biomarkers unleash information related to the effectiveness of the medicine for a particular neurological disorder as well as its side-effects. Citing an instance, uric acid is a key biomarker that helps in detecting the growth of Parkinson ailment and the need for the drug development to inhibit the growth. In addition to this, MRI-based biomarkers help in determining intensity of multiple sclerosis, spinal muscular atrophy, retinal neurodegenerative disorder, and acute ischemic strokes.

Market Growth Dynamics

Technological innovations in genomics, metabolomics, and proteomics are predicted to steer the growth of neurological biomarkers industry over the estimated timeframe. Apparently, large-scale occurrence of the neurological ailments due to stressful & hectic work schedule as well as work-life imbalance will drive the market trends. In addition to this, less proportion of effective diagnostics tools available in emerging countries has resulted in rise in the mortality due to neurological diseases, thereby enhancing the need for neurological biomarkers in these countries.

Furthermore, surge in the neurological disorders like Alzheimer, brain tumors, Parkinson, cerebral stroke, and epilepsy will pave a way for the industry growth over the forecasting years. Apparently, favorable government schemes as well as rise in the investment in neurological diagnostics sector has translated into market demand. Rise in the research activities pertaining to neuroscience and huge funding provided by the government agencies to promote neuro-medicine discoveries will embellish the industry expansion in the coming years.

Asia Pacific Market To Accrue Huge Returns Over 2020-2026

Rise in the occurrence of neurological disorders like Alzheimer and Parkinson among the aging population has generated huge demand for the neurological biomarker, thereby spurring the market growth in the region. Apart from this, rise in the awareness pertaining to neurological diseases and a complete overhaul as well as drastic improvisations witnessed in healthcare infrastructure facilities in the countries like China will magnify the market growth in the Asia Pacific zone. Apart from China, countries like South Korea and India are projected to be the major regional revenue drivers over the next couple of years.

Key players influencing the market growth are Bio-Rad Laboratories, Inc., QIAGEN, Alseres Pharmaceuticals, Inc., Abbott, Thermo Fisher Scientific Inc., Acumen Pharmaceuticals, Myriad RBM, Athena Diagnostics; AbaStar MDx, Inc., and BANYAN BIOMARKERS, INC.

The global neurological biomarkers market is segmented as follows:

By application:

  • Multiple Sclerosis
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Autism Spectrum Disorders
  • Others

By type:

  • Metabolomic
  • Genomic
  • Proteomic
  • Imaging
  • Others

By end-user:

  • Research Organizations
  • Hospital Laboratories
  • Independent Clinical Diagnostic Centers
  • Others

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Type
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Neurulogical Biomarkers Market, 2016–2026(USD Million)
    • 2.2. Neurulogical Biomarkers Market: Snapshot
  • Chapter 3. Global Neurulogical Biomarkers Market– Industry Analysis
    • 3.1. Neurulogical Biomarkers Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Large-scale occurrence of the neurulogical ailments due to stressful & hectic work schedule as well as work-life imbalance will drive the market trends.
      • 3.2.2. Less proportion of effective diagnostics touls available in emerging countries has resulted in rise in the mortality due to neurulogical diseases, thereby enhancing the need for neurulogical biomarkers in these countries.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Type
      • 3.4.2. Market attractiveness analysis By Application
      • 3.4.3. Market attractiveness analysis By End-User
  • Chapter 4. Global Neurulogical Biomarkers Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Neurulogical Biomarkers Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
      • 4.2.5. Price trend analysis
  • Chapter 5. Global Neurulogical Biomarkers Market–Application Analysis
    • 5.1. Global Neurulogical Biomarkers Market overview: By Application
      • 5.1.1. Global Neurulogical Biomarkers Market share, By Application ,2019 and 2026
    • 5.2. Alzheimer’s Disease
      • 5.2.1. Global Neurulogical Biomarkers Market by Alzheimer’s Disease , 2016–2026(USD Million)
    • 5.3. Parkinson’s Disease
      • 5.3.1. Global Neurulogical Biomarkers Market by Parkinson’s Disease, 2016–2026(USD Million)
    • 5.4. Autism Spectrum Disorders
      • 5.4.1. Global Neurulogical Biomarkers Market by Autism Spectrum Disorders, 2016–2026(USD Million)
    • 5.5. Multiple Sclerosis
      • 5.5.1. Global Neurulogical Biomarkers Market by Multiple Sclerosis, 2016–2026(USD Million)
    • 5.6. Others
      • 5.6.1. Global Neurulogical Biomarkers Market by Others, 2016–2026(USD Million)
  • Chapter 6. Global Laser Cutting Machine Market– Type Analysis
    • 6.1. Global Neurulogical Biomarkers Market overview: By Type
      • 6.1.1. Global Neurulogical Biomarkers Market share, By Type, 2019 and 2026
    • 6.2. Proteomic
      • 6.2.1. Global Neurulogical Biomarkers Market By Proteomic, 2016–2026(USD Million)
    • 6.3. Genomic
      • 6.3.1. Global Neurulogical Biomarkers Market By Genomic, 2016–2026(USD Million)
    • 6.4. Imaging
      • 6.4.1. Global Neurulogical Biomarkers Market By Imaging, 2016–2026(USD Million)
    • 6.5. Metabulomic
      • 6.5.1. Global Neurulogical Biomarkers Market By Metabulomic, 2016–2026(USD Million)
    • 6.6. Others
      • 6.6.1. Global Neurulogical Biomarkers Market By Others, 2016–2026(USD Million)
  • Chapter 7. Global Laser Cutting Machine Market– End-User Analysis
    • 7.1. Global Neurulogical Biomarkers Market overview: By End-User
      • 7.1.1. Global Neurulogical Biomarkers Market share, By End-User, 2019 and 2026
    • 7.2. Independent Clinical Diagnostic Centers
      • 7.2.1. Global Neurulogical Biomarkers Market By Independent Clinical Diagnostic Centers, 2016–2026(USD Million)
    • 7.3. Hospital Laboratories
      • 7.3.1. Global Neurulogical Biomarkers Market By Hospital Laboratories, 2016–2026(USD Million)
    • 7.4. Research Organizations
      • 7.4.1. Global Neurulogical Biomarkers Market By Research Organizations, 2016–2026(USD Million)
    • 7.5. Others
      • 7.5.1. Global Neurulogical Biomarkers Market By Others, 2016–2026(USD Million)
  • Chapter 8. Company Profiles
    • 8.1. QIAGEN
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Abbott
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Thermo Fisher Scientific Inc.
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. Myriad RBM
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Developments
    • 8.5. Bio-Rad Laboratories, Inc.
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development
    • 8.6. Athena Diagnostics
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Development
    • 8.7. Acumen Pharmaceuticals
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Development
    • 8.8. AbaStar MDx, Inc.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Development
    • 8.9. Alseres Pharmaceuticals, Inc.
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Development
    • 8.10. BANYAN BIOMARKERS, INC.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Product Portfolio
      • 8.10.4. Business Strategy
      • 8.10.5. Recent Development

Table Of Figures

List of Figures

1. Market research Type
2. Market research methodology
3. Global Neurological Biomarkers Market, 2016–2026(USD Million)
4. Porter’s Five Forces Analysis
5. Global Neurological Biomarkers Market attractiveness, By Type 
6. Global Neurological Biomarkers Market attractiveness, By Application 
7. Global Neurological Biomarkers Market attractiveness, By End-User 
8. Global Neurological Biomarkers Market share, By Application, 2019 and 2026 (USD Million)
9. Global Neurological Biomarkers Market by Alzheimer’s Disease , 2016–2026(USD Million)
10. Global Neurological Biomarkers Market by Parkinson’s Disease,2016–2026(USD Million)
11. Global Neurological Biomarkers Market by Autism Spectrum Disorders,2016–2026(USD Million)
12. Global Neurological Biomarkers Market by Multiple Sclerosis,2016–2026(USD Million)
13. Global Neurological Biomarkers Market by Others,2016–2026(USD Million)
14. Global Neurological Biomarkers Market share by Type,2019 and 2026 (USD Million)
15. Global Neurological Biomarkers Market by Proteomic,2016–2026(USD Million)
16. Global Neurological Biomarkers Market by Genomic,2016–2026(USD Million)
17. Global Neurological Biomarkers Market by Imaging,2016–2026(USD Million)
18. Global Neurological Biomarkers Market by Metabolomic,2016–2026(USD Million)
19. Global Neurological Biomarkers Market by Others,2016–2026(USD Million)
20. Global Neurological Biomarkers Market share by End-User,2019 and 2026 (USD Million)
21. Global Neurological Biomarkers Market by Independent Clinical Diagnostic Centers,2016–2026(USD Million)
22. Global Neurological Biomarkers Market by Hospital Laboratories,2016–2026(USD Million)
23. Global Neurological Biomarkers Market by Research Organizations,2016–2026(USD Million)
24. Global Neurological Biomarkers Market by Others,2016–2026(USD Million)
25. Global Neurological Biomarkers Market share, by Region, 2019 and 2026
26. North America Neurological Biomarkers Market, 2016–2026(USD Million)
27. Europe Neurological Biomarkers Market, 2016–2026(USD Million)
28. Asia Pacific Neurological Biomarkers Market, 2016–2026(USD Million)
29. Latin America Neurological Biomarkers Market, 2016–2026(USD Million)
30. The Middle East and Africa Neurological Biomarkers Market, 2016–2026(USD Million)


Table Of Tables

List of Tables

1. Global Neurological Biomarkers Market: snapshot
2. Drivers of the Neurological Biomarkers Market: impact analysis
3. North America Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
4. North America Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
5. North America Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
6. The U.S. Neurological Biomarkers Market revenue, By Type , 2016–2026(USD Million)
7. The U.S. Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
8. The U.S. Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
9. Rest of North America Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
10. Rest of North America Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
11. Rest of North America Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
12. Europe Neurological Biomarkers Market revenue, By Type , 2016–2026(USD Million)
13. Europe Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
14. Europe Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
15. UK Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
16. UK Neurological Biomarkers Market revenue, By Application, 2016–2026(USD Million)
17. UK Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
18. France Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
19. France Neurological Biomarkers Market revenue, By Application, 2016–2026(USD Million)
20. France Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
21. Germany Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
22. Germany Neurological Biomarkers Market revenue, By Application, 2016–2026(USD Million)
23. Germany Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
24. Rest of Europe Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
25. Rest of Europe Neurological Biomarkers Market revenue, By Application, 2016–2026(USD Million)
26. Rest of Europe Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
27. Asia Pacific Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
28. Asia Pacific Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
29. Asia Pacific Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
30. China Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
31. China Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
32. China Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
33. Japan Neurological Biomarkers Market revenue, By Type , 2016–2026(USD Million)
34. Japan Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
35. Japan Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
36. India Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
37. India Neurological Biomarkers Market revenue, By Application, 2016–2026(USD Million)
38. India Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
39. Rest of Asia Pacific Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
40. Rest of Asia Pacific Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
41. Rest of Asia Pacific Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
42. Latin America Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
43. Latin America Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
44. Latin America Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
45. Brazil Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
46. Brazil Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
47. Brazil Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
48. Rest of Latin America Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
49. Rest of Latin America Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
50. Rest of Latin America Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
51. The Middle East and Africa Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
52. The Middle East and Africa Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
53. The Middle East and Africa Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
54. Saudi Arabia Neurological Biomarkers Market revenue, By Type , 2016–2026(USD Million)
55. Saudi Arabia Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
56. Saudi Arabia Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
57. South Africa Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
58. South Africa Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
59. South Africa Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)
60. Rest of the Middle East & Africa Neurological Biomarkers Market revenue, By Type ,2016–2026(USD Million)
61. Rest of the Middle East & Africa Neurological Biomarkers Market revenue, By Application , 2016–2026(USD Million)
62. Rest of the Middle East & Africa Neurological Biomarkers Market revenue, By End-User , 2016–2026(USD Million)


 

Methodology

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Technological innovations in genomics, metabolomics, and proteomics are predicted to steer the growth of neurological biomarkers industry over the estimated timeframe.

The CAGR of the industry is expected to be nearly 14.5% during the forecast timespan.

Asia Pacific region will contribute sizably towards the global market revenue over the estimated timeline.

The key market participants include Bio-Rad Laboratories, Inc., QIAGEN, Alseres Pharmaceuticals, Inc., Abbott, Thermo Fisher Scientific Inc., Acumen Pharmaceuticals, Myriad RBM, Athena Diagnostics; AbaStar MDx, Inc., and BANYAN BIOMARKERS, INC.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed